Patient distribution in 10-year age groups | Download Scientific Diagram
Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics | Nature Communications
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial - The Lancet Infectious Diseases
Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea | BMJ Open Gastroenterology
Growth (a) and toxin levels (b and c) for C. difficile strain ATCC... | Download Scientific Diagram
A population-based spatio-temporal analysis of Clostridium difficile infection in Queensland, Australia over a 10-year period
JoF | Free Full-Text | Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile | HTML
Growth (a) and toxin levels (b and c) for C. difficile strain UK-14 (an... | Download Scientific Diagram
Risk Factors for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-Analysis | Infection Control & Hospital Epidemiology | Cambridge Core
JoF | Free Full-Text | Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile | HTML
Novel risk factors for recurrent Clostridium difficile infection in children. - Abstract - Europe PMC
Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells | BMC Microbiology | Full Text
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial - The Lancet Infectious Diseases
European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults - Clinical Microbiology and Infection
Microbiota-based markers predictive of development of Clostridioides difficile infection | Nature Communications
Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics | Nature Communications
JoF | Free Full-Text | Lipid Species in the GI Tract are Increased by the Commensal Fungus Candida albicans and Decrease the Virulence of Clostridioides difficile | HTML
Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis - Clinical Microbiology and Infection
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial - The Lancet Infectious Diseases
Microbiota-based markers predictive of development of Clostridioides difficile infection | Nature Communications
Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea | BMJ Open Gastroenterology
A population-based spatio-temporal analysis of Clostridium difficile infection in Queensland, Australia over a 10-year period - Journal of Infection
Proton Pump Inhibitors and C. Difficile: A Review of The Clinical Evidence
Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review - ScienceDirect
Microbiota-based markers predictive of development of Clostridioides difficile infection | Nature Communications
Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells | BMC Microbiology | Full Text
